Related Experiment Video
Updated: Jul 19, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations
Tao Ma1,2, Yan Chen1, Zhi-Gang Yi2
1Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Abstract:
The bromodomain and extra-terminal (BET) proteins act as "readers" for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes. BET protein is associated with transcriptional elongation of genes such as c-MYC and BCL-2, and is involved in the regulation of cell cycle and apoptosis. Meanwhile, BET inhibitors (BETi) have regulatory effects on immune checkpoints, immune cells, and cytokine expression. The role of BET proteins and BETi in a variety of tumors has been studied. This paper reviews the recent research progress of BET and BETi in hematologic tumors (mainly leukemia, lymphoma and multiple myeloma) from cellular level studies, animal studies, clinical trials, drug combination, etc. BETi has a promising future in hematologic tumors, and future research directions may focus on the combination with other drugs to improve the efficacy.
More Related Videos
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

